Obesità

Researchers report that a protein signal called SLIT3 helps brown fat ramp up heat production by coordinating the growth of blood vessels and sympathetic nerves. In experiments using mouse models and human cells and tissue datasets, the team found SLIT3 is cut into two fragments with distinct roles—one linked to vessel growth and the other to nerve expansion—pointing to possible future obesity-treatment strategies aimed at boosting energy expenditure.

20 marzo 2026 Riportato dall'IA

A real-world study of nearly 8,000 patients by Cleveland Clinic researchers shows that stopping injectable semaglutide or tirzepatide often does not lead to major weight regain. Many participants maintained or continued losing weight by restarting treatment, switching medications, or using lifestyle support. This differs from clinical trials where rapid regain was observed.

A new American Heart Association scientific statement published Feb. 25, 2026 in Circulation projects that cardiovascular risk factors such as high blood pressure, obesity and diabetes will become more common among U.S. women by 2050, with particularly steep increases forecast for some younger women and for several racial and ethnic groups.

18 febbraio 2026 Riportato dall'IA

A new Cochrane review of 22 clinical trials shows that intermittent fasting does not lead to greater weight loss than standard diet advice for overweight or obese adults. The analysis, involving nearly 2,000 participants, challenges the popularity of fasting methods amid rising global obesity rates. Researchers emphasize the need for more long-term studies and personalized approaches.

L'Anvisa brasiliana ha approvato lunedì 2 febbraio 2026 l'espansione delle indicazioni terapeutiche del semaglutide, principio attivo di Wegovy e Ozempic. Wegovy può ora essere usato per ridurre il rischio di infarti e ictus negli adulti con malattia cardiovascolare e sovrappeso, mentre Ozempic è indicato per il diabete di tipo 2 associato a malattia renale cronica. L'agenzia sta anche esaminando una richiesta per una versione orale di Wegovy.

28 gennaio 2026 Riportato dall'IA Verificato

Where fat is stored in the body—not only how much—is linked to brain structure and cognition, according to a large MRI study of nearly 26,000 UK Biobank participants. Researchers reported that two fat distribution profiles—one marked by high pancreatic fat and another often described as “skinny fat,” with high fat relative to muscle despite a less-obese appearance—were associated with gray-matter loss, faster brain aging and poorer cognitive outcomes.